Skip to main content
SpringerLink
Log in

Integrative Therapies for People with Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension

  • Chapter
  • First Online:
Integrative Therapies in Lung Health and Sleep

Part of the book series: Respiratory Medicine ((RM,volume 4))

  • 929 Accesses

Abstract

There have been minimal evidence-based studies on the role of ­complementary and alternative medicine (CAM) in patients with interstitial lung disease. Clinical experience demonstrates that patients often use complementary and alternative medical approaches independently without medical advice or guidance. The use of CAM, while biologically plausible, may unknowingly expose the patient to harmful side effects with or without interactions with their prescribed medications. Further research is necessary to determine the role of CAM in patients with interstitial lung diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.

    Google Scholar 

  2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000;161(2 Pt 1):646–64.

    Google Scholar 

  3. King Jr TE. Clinical advances in the diagnosis and therapy of the interstitial lung diseases. Am J Respir Crit Care Med. 2005;172(3):268–79.

    Article  PubMed  Google Scholar 

  4. Schwarz M, King TE. Interstitial lung disease. In: Cosgrove G, Schwaz MI, editors. Approach to the evaluation and diagnosis of interstitial lung disease. 5th ed. Shelton, CT: People’s Medical Publishing House-USA; 2011.

    Google Scholar 

  5. Ryu JH, Daniels CE, Hartman TE, Yi ES. Diagnosis of interstitial lung diseases. Mayo Clin Proc. 2007;82(8):976–86.

    Article  PubMed  Google Scholar 

  6. Raghu G, Collard HR Egan JJ, Martinez FJ, Behr J, et al. on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respirat Crit Care Med 2011;183:788–824.

    Google Scholar 

  7. Lindell KO, Jacobs SS. Idiopathic pulmonary fibrosis. Am J Nurs 2003;103(4):32–42; quiz 43.

    Google Scholar 

  8. Judson M. Sarcoidosis: clinical presentation, diagnosis, and approach to treatment. Am J Med Sci. 2008;335(1):26–33.

    Article  PubMed  Google Scholar 

  9. Tzelepis G, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J. 2008;31:11–20.

    Article  PubMed  CAS  Google Scholar 

  10. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Short-term improvement in exercise capacity and symptoms following exercise training in interstitial lung disease. Thorax. 2008;63(6):549–94.

    Article  PubMed  CAS  Google Scholar 

  11. De Vries J, Drent M. Quality of life and health status in interstitial lung diseases. Curr Opin Pulm Med. 2006;12(5):354–8.

    Article  PubMed  Google Scholar 

  12. Saydah SH, Eberhardt MS. Use of complementary and alternative medicine among adults with chronic diseases: United States 2002. J Altern Complement Med. 2006;12(8):805–12.

    Article  PubMed  Google Scholar 

  13. Metcalfe A, Williams J, McChesney J, Patten SB, Jetté N. Use of complementary and alternative medicine by those with a chronic disease and the general population—results of a national population based survey. BMC Complement Altern Med. 2010;18:10–58.

    Google Scholar 

  14. Anbar RD, Murthy VV. Reestablishment of hope as an intervention for a patient with cystic fibrosis awaiting lung transplantation. J Altern Complement Med. 2010;16(9):1007–10.

    Article  PubMed  Google Scholar 

  15. Mularski RA, Munjas BA, Lorenz KA, Sun S, Robertson SJ, Schmelzer W, Kim AC, Shekelle PG. Randomized controlled trial of mindfulness-based therapy for dyspnea in chronic obstructive lung disease. J Altern Complement Med. 2009;15(10):1083–90.

    Article  PubMed  Google Scholar 

  16. Davis CL, Lewith GT, Broomfield J, Prescott P. A pilot project to assess the methodological issues involved in evaluating acupuncture as a treatment for disabling breathlessness. J Altern Complement Med. 2001;7(6):633–9.

    Article  PubMed  CAS  Google Scholar 

  17. Maa S, Sun MF, Hsu KH, Hung TJ, Chen HC, Yu CT, Wang CH, Lin HC. Effect of acupuncture or acupressure on quality of life of patients with chronic obstructive asthma; a pilot study. J Altern Complement Med. 2003;9(5):659–70.

    Article  PubMed  Google Scholar 

  18. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746–52.

    Article  PubMed  Google Scholar 

  19. Nadrous HF, Pelikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA, Ruy JH. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128(4):2393–9.

    Article  PubMed  Google Scholar 

  20. Nathan SD. Pulmonary hypertension in interstitial lung disease. Int J Clin Pract Suppl. 2008;160:21–8.

    Article  PubMed  Google Scholar 

  21. Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30(4):715–21.

    Article  PubMed  CAS  Google Scholar 

  22. Proudman SM, Stevens WM, Sahhar J, Celemajer D. Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment. Intern Med J. 2007;37(7):485–94.

    Article  PubMed  CAS  Google Scholar 

  23. Shigemitsu H, Nagai S, Sharma OP. Pulmonary hypertension and granulomatous vasculitis in sarcoidosis. Curr Opin Pulm Med. 2007;13(5):434–8.

    PubMed  Google Scholar 

  24. Girgis RE, Mathai SC, Krishnan JA, Wigley FM, Hassoun PM. Long-term outcome of bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. J Heart Lung Transplant. 2005;24(10):1626–31.

    Article  PubMed  Google Scholar 

  25. Polomis D, Runo JR, Meyer KC. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med. 2008;14(5):462–9.

    Article  PubMed  Google Scholar 

  26. Kelly L, Miller MD, Richard S, Liebowitz MD, Newby LK. Complementary and alternative medicine in cardiovascular disease: a review of biologically based approaches. Am Heart J. 2004;147(3):401–11.

    Article  Google Scholar 

  27. Pepping J. Coenzyme Q10. Am J Health Syst Pharm. 1999;56:519–20.

    PubMed  CAS  Google Scholar 

  28. Folkers K, Vadhanavikit S, Mortensen SA. Biochemical rationale and myocardial tissue data on the effective therapy of cardiomyopathy with coenzyme Q10. Proc Natl Acad Sci USA. 1985;82:901–4.

    Article  PubMed  CAS  Google Scholar 

  29. Mortensen SA. Perspectives on therapy of cardiovascular disease with coenzyme Q10 (ubiquinone). Clin Investig. 1993;71(Suppl):S116–23.

    PubMed  CAS  Google Scholar 

  30. Langsjoen PH, Langsjoen PH, Folkers K. Long-term efficacy and safety of coenzyme Q10 therapy for idiopathic dilated cardiomyopathy. Am J Cardiol. 1990;65:521–3.

    Article  PubMed  CAS  Google Scholar 

  31. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive cardiac failure: a long term multicenter randomized study. Clin Investig. 1993;71(Suppl):S134–6.

    PubMed  CAS  Google Scholar 

  32. Soja AM, Mortensen SA. Treatment of CHF with CoQ10 illuminated by meta-analyses of clinical trials. Mol Aspects Med. 1997;18(Suppl):S159–68.

    Article  PubMed  CAS  Google Scholar 

  33. Watson PS, Scalia GM, Galbraith A, et al. Lack of effect of coenzyme Q on left ventricular function in patients with congestive heart failure. J Am Coll Cardiol. 1999;33:1549–52.

    Article  PubMed  CAS  Google Scholar 

  34. Khatta M, Alexander BS, Krichten CM, et al. The effect of coenzyme Q10 in patients with congestive heart failure. Ann Intern Med. 2000;132:636–40.

    PubMed  CAS  Google Scholar 

  35. Combs AB, Porter TH, Folkers K. Anticoagulant activity of naphthoquinone analog of vitamin K and an inhibitor of coenzyme Q10-enzyme systems. Res Commun Chem Pathol Pharmacol. 1976;13:109–14.

    PubMed  CAS  Google Scholar 

  36. Landbo C, Almdal TP. Interaction between warfarin and coenzyme Q10. Ugeskr Laeger. 1998;160:3226–7.

    PubMed  CAS  Google Scholar 

  37. Spigset O. Reduced effect of warfarin caused by ubidecarenone. Lancet. 1994;344:1372–3.

    Article  PubMed  CAS  Google Scholar 

  38. Jellin JM, Gregory PJ, Batz F, et al. Pharmacist’s letter/presciber’s letter natural medicine comprehensive database. 5th ed. Stockton, CA: Therapeutic Research Faculty; 2003. p. 379–82.

    Google Scholar 

  39. Rizos I. Three-year survival of patients with heart failure caused by dilated cardiomyopathy and l-carnitine administration. Am Heart J. 2000;139:S130–3.

    Article  Google Scholar 

  40. Jeejeebhoy F, Keith M, Freeman M, et al. Nutritional supplementation with Myo Vive repletes essential cardiac myocyte nutrients and reduces left ventricular size in patients with left ventricular dysfunction. Am Heart J. 2002;143:1092–100.

    Article  PubMed  CAS  Google Scholar 

  41. Krzeminski T, Chatterjee SS. Ischemia and early reperfusion induced arrhythmias: beneficial effects of an extract of Crataegus oxyacantha L. Pharm Pharmacol Lett. 1993;3:45–8.

    Google Scholar 

  42. Holubarsch CJ, Colucci WS, Meinertz T, et al. Survival and prognosis: investigation of crataegus extract WS 1442 in congestive heart failure (SPICE) rationale, study design and study protocol. Eur J Heart Fail. 2000;2:431–7.

    Article  PubMed  CAS  Google Scholar 

  43. Wiehmayr T, Ernst E. Die therapeutische Wirksamkeit von Crataegus. Fortschr Med. 1996;1–2:27–9.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pulmonary, Allergy and Critical Care Medicine, Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease, University of Pittsburg, Pittsburgh, PA, USA

    Kathleen Oare Lindell PhD, RN, Kevin F. Gibson MD & Hunter C. Champion MD, PhD, FAHA

Authors
  1. Kathleen Oare Lindell PhD, RN
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kevin F. Gibson MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hunter C. Champion MD, PhD, FAHA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kathleen Oare Lindell PhD, RN .

Editor information

Editors and Affiliations

  1. , School of Nursing, University of Minnesota, 308 Harvard St. SE, Minneapolis, 55455, Minnesota, USA

    Linda Chlan

  2. , Department of Pulmonary, Allergy, and Cr, University of Minnesota, 401 East River Road, Minneapolis, 55455, Minnesota, USA

    Marshall I. Hertz

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Lindell, K.O., Gibson, K.F., Champion, H.C. (2012). Integrative Therapies for People with Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, and Pulmonary Arterial Hypertension. In: Chlan, L., Hertz, M. (eds) Integrative Therapies in Lung Health and Sleep. Respiratory Medicine, vol 4. Humana Press. https://doi.org/10.1007/978-1-61779-579-4_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-579-4_5

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-61779-578-7

  • Online ISBN: 978-1-61779-579-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation